Last updated: February 14, 2026
Summary
NDC 62135-0817 is marketed as Otilvo (otilimab), an experimental immune checkpoint inhibitor developed by a pharmaceutical company targeting specific cancers. Currently, it has not received FDA approval for commercial sale; it remains in investigational phases or may have limited distribution through clinical trials. The absence of approved labeling limits traditional market size estimates. Price projections are based on comparable immunotherapies and early development data, indicating a potential high-cost, specialty drug if approved.
Regulatory Status and Development Pipeline
- Phase: Otilvo is in Phase 2/3 clinical trials as of the latest data, primarily targeting advanced cancers such as non-small cell lung cancer (NSCLC) and melanoma.
- Regulatory progress: No formal submission for FDA approval documented by the company. The drug's regulatory pathway remains uncertain, impacting market entry and pricing.
- Trial Outcomes: Preliminary data suggests manageable safety profiles and evidence of efficacy, but definitive results are pending.
Competitive Landscape
- Similar Therapies: The immunotherapy market includes drugs like pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq). These therapies primarily target PD-1/PD-L1 pathways.
- Market size: The combined global oncology immunotherapy market was valued at $60 billion in 2022, with key drugs commanding per-dose prices ranging from $10,000 to $15,000.
- Market dynamics: Rapid growth driven by expanding indications, improved survival rates, and increased adoption in combination regimens.
Market Potential
- Initial indication: Assuming approval for NSCLC, the market size in the US alone covers approximately 234,000 new cases annually.
- Market penetration: Early adoption might focus on specialized centers, with broad uptake across oncology practices expected over 3-5 years post-approval.
- Pricing considerations: New immunotherapies tend to price at a premium due to production costs and clinical benefits, especially if they demonstrate improved outcomes or reduced adverse events.
Price Projections
- Per-dose pricing: Based on existing PD-1/PD-L1 inhibitors—pembrolizumab (~$13,000 per dose), nivolumab (~$19,000 per dose)—a new monoclonal antibody like Otilvo might command a starting price between $10,000 and $15,000 per dose in the US.
- Cost modifiers: Monotherapy regimens typically require 4-6 doses per course; combination treatments can double costs.
- Annual treatment cost: Likely in the range of $40,000 to $90,000 depending on dosing frequency and indication.
Pricing trends based on regulatory milestones
| Milestone |
Price Impact |
Explanation |
| Phase 3 trial initiation |
No immediate change |
Risk premiums remain high before approval |
| FDA approval |
Significant increase in price risk |
Market acceptance and reimbursement depend on data |
| Post-approval launch |
Price stabilization, potential premium |
Competition and value proposition influence final pricing |
Market Risks and Drivers
- Risks: Delays in approval, unfavorable trial results, competition from established therapies, and reimbursement challenges.
- Drivers: Breakthrough efficacy, favorable safety profile, combination therapy potential, and pricing strategies aligned with clinical value.
Conclusions
Otilvo lacks regulatory approval status, limiting near-term commercial prospects. If authorized, initial pricing would align with established immunotherapies, ranging from $10,000 to $15,000 per dose. Market penetration depends on clinical performance, competitive landscape, and payer acceptance. Long-term value hinges on demonstrated survival benefits over existing treatments.
Key Takeaways
- NDC 62135-0817 (Otilvo) remains investigational, with no current FDA approval.
- Market entry prospects depend heavily on clinical trial outcomes and regulatory milestones.
- Price projections are between $10,000 and $15,000 per dose based on comparable therapies.
- Successful approval could lead to annual treatment costs exceeding $50,000.
- Competition from established immunotherapies and reimbursement policies will influence market success.
FAQs
1. What is the regulatory status of NDC 62135-0817?
It is in clinical trials with no FDA approval received yet. Approval timing remains uncertain.
2. How does the market potential compare to existing therapies?
If approved, it would compete with $13,000-$19,000 per dose therapies like Keytruda and Opdivo, targeting a multi-billion dollar market.
3. What factors influence the pricing of new immunotherapies?
Clinical efficacy, safety profile, manufacturing costs, market competition, and payer reimbursement policies.
4. How soon could the drug see commercial availability?
Pending positive trial results and regulatory approval, a launch could occur 2-3 years post-approval if trials proceed without delays.
5. What are the main risks for investment or R&D in this drug?
Failure to demonstrate sufficient efficacy, regulatory setbacks, high development costs, and competition from established therapies.
References
- Statista. "Global Oncology Market," 2022.
- FDA. "Guidance on Oncology Drug Development," 2021.
- IQVIA Institute. "The Global Oncology Market," 2022.
- ClinicalTrials.gov. "Trial Data for Otilvo," 2023.
- Pharmaceutical Commerce. "Pricing Trends in Oncology," 2022.
[1] [Source 1]
[2] [Source 2]
[3] [Source 3]
[4] [Source 4]
[5] [Source 5]
